Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Drug Metabolism And Disposition

• Publication date

  2006-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.106.010553PMID 16790554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic principles of immunosuppressive drugs.

  2008cited by this paper
• Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.

  2006cited by this paper
• The impact of uridine diphosphate–glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single‐nucleotide polymorphisms T—275A and C—2152T on early mycophenolic acid dose‐interval exposure in de novo renal allograft recipients

  2005cited by this paper
• IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM

  2005influential reference
• Pharmacokinetic Principles of Immunosuppressive Drugs

  2005cited by this paper
• Joint Effects between UDP-Glucuronosyltransferase 1A7 Genotype and Dietary Carcinogen Exposure on Risk of Colon Cancer

  2005cited by this paper
• Mycophenolate Mofetil in Islet Cell Transplant: Variable Pharmacokinetics but Good Correlation Between Total and Unbound Concentrations

  2005cited by this paper
• Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin.

  2004cited by this paper
• A novel functional polymorphism in the uridine diphosphate–glucuronosyltransferase 2B7 promoter with significant impact on promoter activity

  2004cited by this paper
• Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

  2004cited by this paper
• The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants.

  2004influential reference
• Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs

  2003cited by this paper
• A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis.

  2002cited by this paper
• Pharmacokinetics and Protein Binding of Mycophenolic Acid in Stable Lung Transplant Recipients

  2002cited by this paper
• The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.

  2002cited by this paper
• Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3.

  2002influential reference
• Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues.

  2002cited by this paper
• Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models

  2001cited by this paper
• Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members.

  2001cited by this paper
• The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes.

  2001cited by this paper
• Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes

  2001cited by this paper
• The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes.

  2001cited by this paper
• A new statistical method for haplotype reconstruction from population data.

  2001cited by this paper
• Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic Acid

  2001cited by this paper
• Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.

  2001cited by this paper
• Familial aggregation of physical activity levels in the Québec Family Study.

  2001cited by this paper
• Relative Enzymatic Activity, Protein Stability, and Tissue Distribution of Human Steroid-Metabolizing UGT2B Subfamily Members**This work was supported by the Medical Research Council of Canada, the Fonds de la Recherche en Santé du Québec, and Endorecherche.

  2001cited by this paper
• Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  2000cited by this paper
• Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance.

  2000cited by this paper
• Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y).

  2000cited by this paper
• Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

  2000cited by this paper
• Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?

  2000cited by this paper
• Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation : Implications for therapeutic drug monitoring

  2000cited by this paper
• 3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7).

  2000cited by this paper
• Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene.

  2000influential reference
• Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.

  1999cited by this paper
• Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines.

  1999cited by this paper
• Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8.

  1998cited by this paper
• UDP-glucuronosyltransferases in human intestinal mucosa.

  1998cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998influential reference
• The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

  1998cited by this paper
• The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268).

  1998cited by this paper
• A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

  1998cited by this paper
• Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration

  1996cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Drug interactions in transplantation.

  1995cited by this paper
• Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.

  1993cited by this paper

• Rationalized immunosuppressant dosing in kidney transplantation: Mycophenolate mofetil AUC monitoring and key updates on tacrolimus exposure.

  2026cites this paper
• Gene polymorphisms associated with immunosuppressant adverse effects in systemic lupus erythematosus: a narrative review

  2025cites this paper
• Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study

  2025cites this paper
• Exploring the Impact of Pharmaceutical Excipient PEG400 on the Pharmacokinetics of Mycophenolic Acid Through In Vitro and In Vivo Experiments

  2024cites this paper
• Influence of UDP-Glucuronosyltransferase Polymorphisms on Mycophenolic Acid Metabolism in Renal Transplant Patients.

  2024cites this paper
• An Integrated Sampling Strategy for Therapeutic Mycophenolic Acid Monitoring in Lung Transplant Recipients.

  2024cites this paper
• Comparative urine metabolomics of mice treated with non-toxic and toxic oral doses of (-)-epigallocatechin-3-gallate.

  2023cites this paper
• Canadian Content in the Pages of Drug Metabolism and Disposition: A Comprehensive Historical Analysis

  2023cites this paper
• Effects of UGT2B7 rs7662029 and rs7439366 polymorphisms on sublingual buprenorphine metabolism in heroin addicts: an improved PCR-RFLP assay for the detection of rs7662029 polymorphism.

  2022cites this paper
• Meta-analysis of the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid

  2022cites this paper
• Racial Disparity in Drug Disposition in the Digestive Tract

  2021cites this paper
• Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 −106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients

  2021cites this paper
• Effect of UGT polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patients.

  2021cites this paper
• Significance of ethnic factors in immunosuppressive therapy management after organ transplantation.

  2020cites this paper
• Pharmacogenomics of Immunosuppressants

  2020cites this paper
• Mycophenolic acid pharmacogenomics in kidney transplantation

  2020cites this paper
• Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients

  2019cites this paper
• Impact of SLCO1B3 Polymorphisms on Clinical Outcomes in Lung Allograft Recipients Receiving Mycophenolic Acid

  2019cites this paper
• Limited Sampling Strategy for the Estimation of Mycophenolic Acid and its Acyl Glucuronide Metabolite Area under the Concentration-Time Curve in Japanese Lung Transplant Recipients.

  2019cites this paper
• Mycophenolates: The latest modern and potent immunosuppressive drugs in adult kidney transplantation: what we should know about them?

  2019cites this paper
• Mycophenolic Acid and Its Pharmacokinetic Drug‐Drug Interactions in Humans: Review of the Evidence and Clinical Implications

  2019cites this paper
• In Vitro Study on Influences of UGT1A8 Gene Polymorphisms on Mycophenolate Mofetil Metabolism.

  2018cites this paper
• Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant

  2018cites this paper
• Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients

  2018cites this paper
• Preventing the transmission of mitochondrial diseases

  2017cites this paper
• Meta-analysis reveals a lack of association between MRP2 C-24T genetic polymorphism and the pharmacokinetics of mycophenolic acid in adult renal transplant recipients

  2017cites this paper
• Effect of uridine diphosphate-glucuronosyltransferase polymorphisms on the plasma concentrations of mycophenolic acid in Turkish renal transplant patients

  2017influential citation
• UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.

  2016cites this paper
• Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium

  2016cites this paper
• 1-Alpha, 25-dihydroxyvitamin D3 alters the pharmacokinetics of mycophenolic acid in renal transplant recipients by regulating two extrahepatic UDP-glucuronosyltransferases 1A8 and 1A10.

  2016cites this paper
• Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients

  2015cites this paper
• Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity.

  2015cites this paper
• PharmGKB summary: mycophenolic acid pathway

  2014cites this paper
• Découverte de nouveaux marqueurs pharmacogénomiques de la maladie du greffon contre l'hôte en transplantation de cellules souches hématopoïétiques

  2014cites this paper
• A Population Pharmacokinetic Analysis for Enteric-coated Mycophenolate Sodium Using Non-linear Mixed Effect Model in Korean Kidney Transplant Recipients

  2014cites this paper
• Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients

  2014cites this paper
• Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

  2014cites this paper
• Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients

  2014influential citation
• A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis

  2014cites this paper
• Relevance of Ethylglucuronide as a marker of alcohol consumption : development of dosage methods and study of factors potentially affecting its production

  2013cites this paper
• Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1α and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.

  2013cites this paper
• Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights

  2013cites this paper
• The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7

  2013cites this paper
• Practical and clinical use of opioids

  2013cites this paper
• Effect of UDP-glucuronosyltransferase 1A8 polymorphism on raloxifene glucuronidation.

  2013cites this paper
• Uridine diphosphate glucuronosyltransferase 2B7 variant p.His268Tyr as a predictor of kidney allograft early acute rejection.

  2013cites this paper
• Personalización del tratamiento inmunosupresor con tacrolimo en pacientes con trasplante renal

  2013cites this paper
• The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.

  2012cites this paper
• The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.

  2012cites this paper
• Recent Updates and Potential Clinical Applications

  2012cites this paper
• Pharmacogenetics in Kidney Transplantation

  2012influential citation
• Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers

  2012cites this paper
• The influence of UGT polymorphisms as biomarkers in solid organ transplantation.

  2012cites this paper
• Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid.

  2012cites this paper
• UGT1A9, UGT2B7, and MRP2 Genotypes Can Predict Mycophenolic Acid Pharmacokinetic Variability in Pediatric Kidney Transplant Recipients

  2012influential citation
• UDP‐Glucuronosyltransferases: Pharmacogenetics, Functional Characterization, and Clinical Relevance

  2012cites this paper
• Pharmacogenomics of Immunosuppressants

  2012cites this paper
• The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation

  2011cites this paper
• Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

  2011cites this paper
• Diabetes Mellitus Reduces Activity of Human UDP-Glucuronosyltransferase 2B7 in Liver and Kidney Leading to Decreased Formation of Mycophenolic Acid Acyl-Glucuronide Metabolite

  2011cites this paper
• Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients

  2011cites this paper
• Production of Ibuprofen Acyl Glucosides by Human UGT2B7

  2011cites this paper
• The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease

  2011cites this paper
• Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen.

  2011cites this paper
• Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

  2011cites this paper
• Pharmacogenetics and Renal Transplantation

  2011cites this paper
• Functional expression of uridine diphospho glucuronosyltransferases in fission yeast

  2011cites this paper
• Mykofenolats farmakogenetikk : Etablering og validering av metoder for UGT1A9-genotyping

  2011cites this paper
• UDP-glucuronosyltransferase 2B7 glucuronidation of the active tamoxifen metabolites

  2011cites this paper
• Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.

  2010cites this paper
• Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal‐Transplant Patients

  2010influential citation
• Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients

  2010cites this paper
• Alternatively Spliced Products of the UGT1A Gene Interact with the Enzymatically Active Proteins to Inhibit Glucuronosyltransferase Activity In Vitro

  2010cites this paper
• UGT2B7_−161C>T Polymorphism Is Associated With Lamotrigine Concentration-to-Dose Ratio in a Multivariate Study

  2010cites this paper
• Pharmacogenetic influences on mycophenolate therapy.

  2010cites this paper
• Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis

  2010cites this paper
• Disposition of mycophenolic acid and its glucuronide metabolites in subjects with glomerulonephritis: Implications of genes and effects on kidney outcomes

  2010influential citation
• Genetic polymorphism in metabolism and host defense enzymes: Implications for human health risk assessment

  2010cites this paper
• Pharmacogenetic Impact of UDP‐Glucuronosyltransferase Metabolic Pathway and Multidrug Resistance—Associated Protein 2 Transport Pathway on Mycophenolic Acid in Thoracic Transplant Recipients: An Exploratory Study

  2010cites this paper
• SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients.

  2010cites this paper
• Phenotype prediction of nonsynonymous single nucleotide polymorphisms in human phase II drug/xenobiotic metabolizing enzymes: perspectives on molecular evolution

  2010cites this paper
• Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele.

  2010cites this paper
• Effects of Dietary Factors on Drug Transport and Metabolism: The Impact on Dosage Guidelines in Transplant Patients

  2009cites this paper
• Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs.

  2009cites this paper
• Improving Hematopoietic Cell Transplantation Therapeutics: Emphasis in Pharmacokinetic-Pharmacodynamic Relationships and Pharmacogenomics

  2009cites this paper
• UGT Genotype May Contribute to Adverse Events Following Medication With Mycophenolate Mofetil in Pediatric Kidney Transplant Recipients

  2009cites this paper
• UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus‐Treated Kidney Transplant Patients

  2009cites this paper
• In Vitro Glucuronidation of Fenofibric Acid by Human UDP-Glucuronosyltransferases and Liver Microsomes

  2009cites this paper
• Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.

  2009cites this paper
• Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants

  2009cites this paper
• In vitro glucuronidation of fenofibric acid by human UGTs and liver microsomes.

  2009cites this paper
• Genetic Polymorphisms of MRP2 and UGT2B7 and Gastrointestinal Symptoms in Renal Transplant Recipients Taking Mycophenolic Acid

  2009cites this paper
• Analysis of inherited genetic variations at the UGT1 locus in the French‐Canadian population

  2009cites this paper
• Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention

  2009cites this paper
• IMPDH 1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients

  2008cites this paper
• Comparison of Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Between Patients With Lupus Nephritis and With Kidney Transplantation

  2008cites this paper
• The Importance of Gut Wall Metabolism in Determining Drug Bioavailability

  2008cites this paper
• Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients

  2008cites this paper
• Determination of mycophenolic acid glucuronide in microsomal incubations using high performance liquid chromatography-tandem mass spectrometry.

  2008cites this paper
• IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients

  2008cites this paper